Pan-cancer Analysis of CLDN18.2 Shed New Insights on the Targeted Therapy of Upper Gastrointestinal Tract Cancers

Overview

Journal Front Pharmacol

Date 2024 Nov 18

PMID 39555091

Authors

Jun Wu

Jinghua Lu

Qiuyue Chen

Haojie Chen

Yongqiang Zheng

Minggang Cheng

Affiliations

Soon will be listed here.

Abstract

Background: CLDN18.2 is a widely researched drug target. However, previous research has primarily been based on immunohistochemistry results and focused on gastric cancer.

Methods: To analyze the potential cancer-targeting effect of CLDN18.2 from a multi-omics perspective, this study quantified CLDN18.2 expression in The Cancer Genome Atlas (TCGA) pan-cancer cohort. Thus, the relationships between CLDN18.2 expression and genomic alterations, immune infiltration, and prognosis were analyzed. Additionally, we performed analyses of the differentially expressed genes and enriched pathways between the high- and low-CLDN18.2 expression groups, as well as the corresponding drug sensitivity analyses.

Results: The results indicated that CLDN18.2 was highly expressed in pancreatic adenocarcinoma (PAAD), stomach adenocarcinoma (STAD), colorectal cancer (CRC), and esophageal carcinoma (ESCA). Moreover, the high- and low-CLDN18.2 expression groups presented significant differences in terms of genomic alterations and immune infiltration, such as the levels of methylation and CD4 T cell infiltration. Furthermore, high CLDN18.2 expression was significantly associated with poor prognosis in bladder urothelial carcinoma (BLCA), ESCA, and PAAD. In upper gastrointestinal tract cancers (STAD, ESCA, and PAAD), downregulated gene-enriched pathways were associated with cell signaling, whereas upregulated gene-enriched pathways were associated with angiogenesis. Finally, we identified drugs associated with CLDN18.2 expression to which samples with different levels of expression were differentially sensitive.

Conclusion: CLDN18.2 was highly expressed in upper gastrointestinal tract cancers, and its expression had a significant effect on genomic alterations and the tumor microenvironment. Additionally, low CLDN18.2 expression was linked to favorable prognosis. Our study reveals the potential value of CLDN18.2 for tumor prognosis and targeted therapy in various cancers, especially upper gastrointestinal tract cancers.

References

Oshi M, Roy A, Yan L, Kinoshita S, Tamura Y, Kosaka T . Enhanced epithelial-mesenchymal transition signatures are linked with adverse tumor microenvironment, angiogenesis and worse survival in gastric cancer. Cancer Gene Ther. 2024; 31(5):746-754. DOI: 10.1038/s41417-024-00756-w. View

Kwak Y, Kim T, Nam S, Hwang H, Han D, Oh H . Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression. Oncologist. 2024; 30(2). PMC: 11881060. DOI: 10.1093/oncolo/oyae238. View

Yan J, Zhao W, Yu W, Cheng H, Zhu B . LRRK2 correlates with macrophage infiltration in pan-cancer. Genomics. 2021; 114(1):316-327. DOI: 10.1016/j.ygeno.2021.11.037. View

Jiang H, Shi Z, Wang P, Wang C, Yang L, Du G . Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer. J Natl Cancer Inst. 2018; 111(4):409-418. DOI: 10.1093/jnci/djy134. View

Song Z, Song X, Li H, Cheng Z, Mo Z, Yang X . Identification and validation of a prognostic-related mutant gene for hepatocellular carcinoma. Front Immunol. 2023; 14:1236995. PMC: 10630911. DOI: 10.3389/fimmu.2023.1236995. View

Goldman M, Craft B, Hastie M, Repecka K, McDade F, Kamath A . Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020; 38(6):675-678. PMC: 7386072. DOI: 10.1038/s41587-020-0546-8. View

Stark R, Grzelak M, Hadfield J . RNA sequencing: the teenage years. Nat Rev Genet. 2019; 20(11):631-656. DOI: 10.1038/s41576-019-0150-2. View

Cerami E, Gao J, Dogrusoz U, Gross B, Sumer S, Aksoy B . The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5):401-4. PMC: 3956037. DOI: 10.1158/2159-8290.CD-12-0095. View

Shitara K, Lordick F, Bang Y, Enzinger P, Ilson D, Shah M . Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3.... Lancet. 2023; 401(10389):1655-1668. DOI: 10.1016/S0140-6736(23)00620-7. View

10.

Gu Z, Wang L, Dong Q, Xu K, Ye J, Shao X . Aberrant LYZ expression in tumor cells serves as the potential biomarker and target for HCC and promotes tumor progression via csGRP78. Proc Natl Acad Sci U S A. 2023; 120(29):e2215744120. PMC: 10629575. DOI: 10.1073/pnas.2215744120. View

11.

Falanga A, Marchetti M, Vignoli A . Coagulation and cancer: biological and clinical aspects. J Thromb Haemost. 2013; 11(2):223-33. DOI: 10.1111/jth.12075. View

12.

Xu Y, Fu J, Henderson M, Lee F, Jurcak N, Henn A . CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer. Gastroenterology. 2023; 165(5):1219-1232. PMC: 11008763. DOI: 10.1053/j.gastro.2023.06.037. View

13.

Nakayama I, Qi C, Chen Y, Nakamura Y, Shen L, Shitara K . Claudin 18.2 as a novel therapeutic target. Nat Rev Clin Oncol. 2024; 21(5):354-369. DOI: 10.1038/s41571-024-00874-2. View

14.

Garber M, Grabherr M, Guttman M, Trapnell C . Computational methods for transcriptome annotation and quantification using RNA-seq. Nat Methods. 2011; 8(6):469-77. DOI: 10.1038/nmeth.1613. View

15.

Singhal A, Li B, OReilly E . Targeting KRAS in cancer. Nat Med. 2024; 30(4):969-983. PMC: 11845254. DOI: 10.1038/s41591-024-02903-0. View

16.

Shah M, Shitara K, Ajani J, Bang Y, Enzinger P, Ilson D . Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023; 29(8):2133-2141. PMC: 10427418. DOI: 10.1038/s41591-023-02465-7. View

17.

Schaue D, McBride W . Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol. 2015; 12(9):527-40. PMC: 8396062. DOI: 10.1038/nrclinonc.2015.120. View

18.

Monteith G, Prevarskaya N, Roberts-Thomson S . The calcium-cancer signalling nexus. Nat Rev Cancer. 2017; 17(6):367-380. DOI: 10.1038/nrc.2017.18. View

19.

Khalafi S, Zhu S, Khurana R, Lohse I, Giordano S, Corso S . A novel strategy for combination of clofarabine and pictilisib is synergistic in gastric cancer. Transl Oncol. 2021; 15(1):101260. PMC: 8571525. DOI: 10.1016/j.tranon.2021.101260. View

20.

Lee W, Wang C, Lin T, Hsiao C, Luo C . CXCL17, an orphan chemokine, acts as a novel angiogenic and anti-inflammatory factor. Am J Physiol Endocrinol Metab. 2012; 304(1):E32-40. DOI: 10.1152/ajpendo.00083.2012. View